The MALAT1-breast cancer interplay: insights and implications

References

• Buranjiang G, Abuduwanke A, Li X, et al. LncRNA HOTAIR enhances RCC2 to accelerate cervical cancer progression by sponging miR-331-3p. Clin Transl Oncol. 2023;25(6):1–11. doi: 10.1007/s12094-022-03059-4
   PubMed Web of Science ®Google Scholar
• Mahmoud AA, Mohamed HO, AA AM, et al. Long noncoding RNA HOTAIR and Midkine as biomarkers in thyroid cancer. Egypt J Immunol. 2023;30(1):96–104. doi: 10.55133/eji.300113
   PubMedGoogle Scholar
• Asadi M, Gholampour MA, Kompani F, et al. Expression of long non-coding RNA H19 in acute lymphoblastic Leukemia. Cell J (Yakhteh). 2023;25(1):1.
   PubMedGoogle Scholar
• Ghapanchi J, Mokhtari MJ, Zahed M, et al. Genetic analysis of lncRNA H19 (rs217727) and MIAT (rs1894720) polymorphisms in patients with salivary gland tumors. Gene Rep. 2023;30:101724. doi: 10.1016/j.genrep.2022.101724
   Web of Science ®Google Scholar
• Dong L, Wang H, Gao Y, et al. Long non‑coding RNA PVT1 promotes the proliferation, migration and EMT process of ovarian cancer cells by regulating CTGF. Oncol Lett. 2023;25(2):1–7. doi: 10.3892/ol.2022.13657
   PubMed Web of Science ®Google Scholar
• Roohinejad Z, Bahramian S, Shamsabadi FT, et al. Upregulation of the c-MYC oncogene and adjacent long noncoding RNAs PVT1 and CCAT1 in esophageal squamous cell carcinoma. BMC Cancer. 2023;23(1):34. doi: 10.1186/s12885-022-10464-z
   PubMed Web of Science ®Google Scholar
• Falese JP, McFadden EJ, Hargrove AE. Structure‐function relationships for the lncRNA SChLAP1 in aggressive prostate cancer. Faseb J. 2022;36(S1). doi: 10.1096/fasebj.2022.36.S1.0R251
   Google Scholar
• Jiang W, Xie R, Chen X, et al. Functions and clinical significances of LncRNA SChLAP1 and UBE2E3 in prostate cancer. 2022.
   Google Scholar
• Haghighi N, Doosti A, Kiani J. Evaluation of apoptosis, cell proliferation and cell cycle progression by inactivation of the NEAT1 long noncoding RNA in a renal carcinoma cell line using CRISPR/Cas9. Iran J Biotechnol. 2023;21(1):63–78.
   Google Scholar
• Zhang P, Gao J, Lin S, et al. Long non‑coding RNA NEAT1 promotes mouse granulosa cell proliferation and estradiol synthesis by sponging miR‑874‑3p. Exp Ther Med. 2023;25(1):1–8. doi: 10.3892/etm.2022.11731
   PubMed Web of Science ®Google Scholar
• Li T, Xie J, Shen C, et al. Amplification of long noncoding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma. Cancer Res. 2015;75(15):3181–3191. doi: 10.1158/0008-5472.CAN-14-3721
   PubMed Web of Science ®Google Scholar
• Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–1504. doi: 10.1101/gad.1800909
   PubMed Web of Science ®Google Scholar
• Schorderet P, Duboule D, Bickmore WA. Structural and functional differences in the long non-coding RNA hotair in mouse and human. PLoS Genet. 2011;7(5):e1002071. doi: 10.1371/journal.pgen.1002071
   PubMed Web of Science ®Google Scholar
• Cao Y, Di X, Cong S, et al. RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC. Life Sci. 2023;315:121359. doi: 10.1016/j.lfs.2022.121359
   PubMed Web of Science ®Google Scholar
• Xin R, Hu B, Qu D, et al. Oncogenic lncRNA MALAT-1 recruits E2F1 to upregulate RAD51 expression and thus promotes cell autophagy and tumor growth in non-small cell lung cancer. Pulm Pharmacol Ther. 2023;102199:102199. doi: 10.1016/j.pupt.2023.102199
   Google Scholar
• Li S, Jiang F, Chen F, et al. Effect of m6A methyltransferase METTL3‐mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer. J Biochem & Molecular Tox. 2022;36(1):e22922. doi: 10.1002/jbt.22922
   PubMed Web of Science ®Google Scholar
• Li J, Liu H, Lin Q, et al. Baicalin suppresses the migration and invasion of breast cancer cells via the TGF-β/lncRNA-MALAT1/miR-200c signaling pathway. Medicine. 2022;101(46):e29328. doi: 10.1097/MD.0000000000029328
   PubMed Web of Science ®Google Scholar
• Yang F, Wang M, Shi J, et al. IncRNA MALAT1 regulates the proliferation, apoptosis, migration, and invasion of osteosarcoma cells by targeting miR-873-5p/ROCK1. Crit Rev Eukaryot Gene Expr. 2023;33(2):67–79. doi: 10.1615/CritRevEukaryotGeneExpr.2022044747
   PubMed Web of Science ®Google Scholar
• Farzaneh M, Najafi S, Anbiyaee O, et al. LncRNA MALAT1-related signaling pathways in osteosarcoma. Clin Transl Oncol. 2022;25(1):1–12. doi: 10.1007/s12094-022-02876-x
   PubMed Web of Science ®Google Scholar
• Xu W-W, Jin J, X-Y W, et al. MALAT1-related signaling pathways in colorectal cancer. Cancer Cell Int. 2022;22(1):1–9. doi: 10.1186/s12935-021-02402-z
   PubMed Web of Science ®Google Scholar
• Cervena K, Vodenkova S, Vymetalkova V. MALAT1 in colorectal cancer: Its implication as a diagnostic, prognostic, and predictive biomarker. Gene. 2022;146791:146791. doi: 10.1016/j.gene.2022.146791
   Google Scholar
• Liao X, Chen J, Luo D, et al. Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation. Pathol Oncol Res. 2023;142: doi: 10.3389/pore.2022.1610808
   Google Scholar
• Choi HI, An GY, Yoo E, et al. The bromodomain inhibitor JQ1 up-regulates the long non-coding RNA MALAT1 in cultured human hepatic carcinoma cells. Sci Rep. 2022;12(1):7779. doi: 10.1038/s41598-022-11868-4
   PubMed Web of Science ®Google Scholar
• Hutchinson JN, Ensminger AW, Clemson CM, et al. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics. 2007;8(1):1–16. doi: 10.1186/1471-2164-8-39
   PubMedGoogle Scholar
• Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Molecular Cell. 2010;39(6):925–938. doi: 10.1016/j.molcel.2010.08.011
   PubMed Web of Science ®Google Scholar
• Eißmann M, Gutschner T, Hämmerle M, et al. Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol. 2012;9(8):1076–1087. doi: 10.4161/rna.21089
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Ip JY, Shioi G, et al. Malat1 is not an essential component of nuclear speckles in mice. RNA. 2012;18(8):1487–1499. doi: 10.1261/rna.033217.112
   PubMed Web of Science ®Google Scholar
• Zhang R, Xia Y, Wang Z, et al. Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer. Biochem Biophys Res Commun. 2017;490(2):406–414. doi: 10.1016/j.bbrc.2017.06.055
   PubMed Web of Science ®Google Scholar
• Tong G, Tong W, He R, et al. MALAT1 polymorphisms and lung cancer susceptibility in a Chinese Northeast han population. Int J Med Sci. 2022;19(8):1300. doi: 10.7150/ijms.73026
   PubMed Web of Science ®Google Scholar
• Yue X, W-Y W, Dong M, et al. LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570–3p. Biomed J. 2021;44(6):S296–S304. doi: 10.1016/j.bj.2020.11.002
   PubMed Web of Science ®Google Scholar
• Huang XJ, Xia Y, He GF, et al. MALAT1 promotes angiogenesis of breast cancer. Oncol Rep. 2018;40(5):2683–2689. doi: 10.3892/or.2018.6705
   PubMed Web of Science ®Google Scholar
• Zhang B, Mao YS, Diermeier SD, et al. Identification and characterization of a class of MALAT1-like genomic loci. Cell Rep. 2017;19(8):1723–1738. doi: 10.1016/j.celrep.2017.05.006
   PubMed Web of Science ®Google Scholar
• Peng R, Luo C, Guo Q, et al. Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population. Gene. 2018;642:241–248. doi: 10.1016/j.gene.2017.11.013
   PubMed Web of Science ®Google Scholar
• Elbasateeny SS, Yassin MA, Mokhtar MM, et al. Prognostic implications of MALAT1 and BACH1 expression and their correlation with CTCs and Mo-MDSCs in triple negative breast cancer and surgical management options. Int J Breast Cancer. 2022;2022:1–13. doi: 10.1155/2022/8096764
   Web of Science ®Google Scholar
• Miao Y, Fan R, Chen L, et al. Clinical significance of long non-coding RNA MALAT1 expression in tissue and serum of breast cancer. Ann Clini Lab Sci. 2016;46(4):418–424.
   PubMed Web of Science ®Google Scholar
• Li L, Feng T, Lian Y, et al. Role of human noncoding RNAs in the control of tumorigenesis. Proc Nat Acad Sci. 2009;106(31):12956–12961. doi: 10.1073/pnas.0906005106
   PubMed Web of Science ®Google Scholar
• Latorre E, Carelli S, Raimondi I, et al. The ribonucleic complex HuR-MALAT1 represses CD133 expression and suppresses epithelial–mesenchymal transition in breast CancerEMT can be modulated by fine tuning MALAT1 and HuR. Cancer Res. 2016;76(9):2626–2636. doi: 10.1158/0008-5472.CAN-15-2018
   PubMed Web of Science ®Google Scholar
• Guy CT, Cardiff R, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12(3):954–961. doi: 10.1128/mcb.12.3.954-961.1992
   PubMed Web of Science ®Google Scholar
• Zhang B, Arun G, Mao YS, et al. The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep. 2012;2(1):111–123. doi: 10.1016/j.celrep.2012.06.003
   PubMed Web of Science ®Google Scholar
• Zhang X, Tang X, Hamblin MH, et al. Long non-coding RNA Malat1 regulates angiogenesis in hindlimb ischemia. Int J Mol Sci. 2018;19(6):1723. doi: 10.3390/ijms19061723
   PubMed Web of Science ®Google Scholar
• Arun G, Spector DL. MALAT1 long non-coding RNA and breast cancer. RNA Biol. 2019;16(6):860–863. doi: 10.1080/15476286.2019.1592072
   PubMed Web of Science ®Google Scholar
• Kim J, Piao H-L, Kim B-J, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nature Genet. 2018;50(12):1705–1715. doi: 10.1038/s41588-018-0252-3
   PubMed Web of Science ®Google Scholar
• MALAT1 Long Non-Coding RNA: functional Implications. Non-Coding RNA, 2020. p. 2311–553X .
   Google Scholar
• Gao H, Chakraborty G, Lee-Lim AP, et al. Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. Proc Nat Acad Sci. 2014;111(46):16532–16537. doi: 10.1073/pnas.1403234111
   PubMed Web of Science ®Google Scholar
• Arun G, Diermeier S, Akerman M, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev. 2016;30(1):34–51. doi: 10.1101/gad.270959.115
   PubMed Web of Science ®Google Scholar
• Jadaliha M, Zong X, Malakar P, et al. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget. 2016;7(26):40418. doi: 10.18632/oncotarget.9622
   PubMedGoogle Scholar
• Xiping Z, Bo C, Shifeng Y, et al. Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer. Oncotarget. 2018;9(2):2255. doi: 10.18632/oncotarget.23370
   PubMedGoogle Scholar
• Wang Z, Katsaros D, Biglia N, et al. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival. Breast Cancer Res Treat. 2018;171(2):261–271. doi: 10.1007/s10549-018-4839-2
   PubMed Web of Science ®Google Scholar
• Guffanti A, Iacono M, Pelucchi P, et al. A transcriptional sketch of a primary human breast cancer by 454 deep sequencing. BMC Highly accessed paper. (2009).
   Google Scholar
• Huang Z, Qin Q, Xia L, et al. Significance of oncotype DX 21-gene test and expression of long non-coding RNA MALAT1 in early and estrogen receptor-positive breast cancer patients. Cancer Manage Res. 2021;13:587. doi: 10.2147/CMAR.S276795
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhang Y, Fu Y, et al. Long non-coding RNA MALAT1 regulates BLCAP mRNA expression through binding to miR-339-5p and promotes poor prognosis in breast cancer. Biosci Rep. 2019;39(2): doi: 10.1042/BSR20181284
   Google Scholar
• Liu H, Tang L, Li X, et al. Triptolide inhibits vascular endothelial growth factor‑mediated angiogenesis in human breast cancer cells. Exp Ther Med. 2018;16(2):830–836. doi: 10.3892/etm.2018.6200
   PubMed Web of Science ®Google Scholar
• Pruszko M, Milano E, Forcato M, et al. The mutant p53‐ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Rep. 2017;18(8):1331–1351. doi: 10.15252/embr.201643370
   PubMed Web of Science ®Google Scholar
• Turco C, Esposito G, Iaiza A, et al. MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. Commun Biol. 2022;5(1):598. doi: 10.1038/s42003-022-03539-x
   PubMed Web of Science ®Google Scholar
• Jiao LR, Frampton AE, Jacob J, et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One. 2012;7(2):e32068. doi: 10.1371/journal.pone.0032068
   PubMed Web of Science ®Google Scholar
• Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087–2092. doi: 10.1111/j.1349-7006.2010.01650.x
   PubMed Web of Science ®Google Scholar
• Hironaka-Mitsuhashi A, Takayama S, Jimbo K, et al. Clinical application of MicroRNAs in breast cancer treatment. Archives Of Breast Cancer. 2022;20–31. doi: 10.32768/abc.20229120-31
   Google Scholar
• Xia C, Yang Y, Kong F, et al. MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. Biochimie. 2018;147:98–104. doi: 10.1016/j.biochi.2018.01.003
   PubMed Web of Science ®Google Scholar
• Fattahi Dolatabadi N, Dehghani A, Shahand E, et al. The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer. Hum Cell. 2020;33(4):1229–1239. doi: 10.1007/s13577-020-00422-x
   PubMed Web of Science ®Google Scholar
• He Y, Deng F, Zhao S, et al. Analysis of miRNA–mRNA network reveals miR-140-5p as a suppressor of breast cancer glycolysis via targeting GLUT1. Epigenomics. 2019;11(9):1021–1036. doi: 10.2217/epi-2019-0072
   PubMed Web of Science ®Google Scholar
• Shih C-H, Chuang L-L, Tsai M-H, et al. Hypoxia-induced MALAT1 promotes the proliferation and migration of breast cancer cells by sponging MiR-3064-5p. Front Oncol. 2021;11:658151. doi: 10.3389/fonc.2021.658151
   PubMedGoogle Scholar
• Ma P, Ni K, Ke J, et al. MiR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2. Exp Biol Med. 2018;243(5):473–480. doi: 10.1177/1535370218754848
   Web of Science ®Google Scholar
• Bamodu OA, Huang W-C, Lee W-H, et al. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer. 2016;16(1):160. doi: 10.1186/s12885-016-2108-5
   PubMed Web of Science ®Google Scholar
• Ji Q, Liu X, Fu X, et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. PLoS One. 2013;8(11):e78700. doi: 10.1371/journal.pone.0078700
   PubMed Web of Science ®Google Scholar
• Ying L, Chen Q, Wang Y, et al. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012;8(9):2289–2294. doi: 10.1039/c2mb25070e
   PubMedGoogle Scholar
• Xu S, Sui S, Zhang J, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int J Clin Exp Pathol. 2015;8(5):4881.
   PubMed Web of Science ®Google Scholar
• Bejarano L, Jordāo MJ, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discovery. 2021;11(4):933–959. doi: 10.1158/2159-8290.CD-20-1808
   PubMed Web of Science ®Google Scholar
• Mao T-L, Fan M-H, Dlamini N, et al. LncRNA MALAT1 facilitates ovarian cancer progression through promoting chemoresistance and invasiveness in the tumor microenvironment. Int J Mol Sci. 2021;22(19):10201. doi: 10.3390/ijms221910201
   PubMed Web of Science ®Google Scholar
• Soliman RA, Youness RA, Manie TM, et al. Uncoupling tumor necrosis factor-α and interleukin-10 at tumor immune microenvironment of breast cancer through miR-17-5p/MALAT-1/H19 circuit. Biocell. 2022;46(3):769. doi: 10.32604/biocell.2022.016636
   Web of Science ®Google Scholar
• Quijia CR, Chorilli M. Piperine for treating breast cancer: A review of molecular mechanisms, combination with anticancer drugs, and nanosystems. Phytother Res. 2022;36(1):147–163. doi: 10.1002/ptr.7291
   PubMed Web of Science ®Google Scholar
• Singla RK, Wang X, Gundamaraju R, et al. Natural products derived from medicinal plants and microbes might act as a game-changer in breast cancer: a comprehensive review of preclinical and clinical studies. Crit Rev Food Sci Nutr. 2022;1–45.
   PubMed Web of Science ®Google Scholar
• Alam A, Al Arif Jahan A, Bari MS, et al. Allium vegetables: Traditional uses, phytoconstituents, and beneficial effects in inflammation and cancer. Crit Rev Food Sci Nutr. 2022;1–35.
   PubMed Web of Science ®Google Scholar
• Kaur B, Rolta R, Salaria D, et al. An in silico investigation to explore anti-cancer potential of Foeniculum vulgare Mill. Phytoconstituents for the management of human breast cancer. Molecules. 2022;27(13):4077. doi: 10.3390/molecules27134077
   PubMed Web of Science ®Google Scholar
• Zhou G, Boor PP, Bruno MJ, et al. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer. 2022;126(1):10–23. doi: 10.1038/s41416-021-01453-3
   PubMed Web of Science ®Google Scholar
• Giannotta C, Autino F, Massaia M. The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells. Front Immunol. 2023;13:1102471–1102478. doi: 10.3389/fimmu.2022.1102471
   PubMed Web of Science ®Google Scholar
• Soliman R, Youness R, Handoussa H, et al. 25P Promising immuno-oncological role of rosemary against breast cancer through altering miR-17-5p, MALAT-1, H19 and tumour microenvironment. Ann Oncol. 2021;32:S11. doi: 10.1016/j.annonc.2021.01.039
   Web of Science ®Google Scholar
• Kim H, Choi J-M, Lee K-M. Immune checkpoint blockades in triple-negative breast cancer: Current state and molecular mechanisms of resistance. Biomedicines. 2022;10(5):1130. doi: 10.3390/biomedicines10051130
   PubMed Web of Science ®Google Scholar
• Li H, Yang P, Wang J, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol. 2022;15(1):1–6. doi: 10.1186/s13045-021-01223-x
   PubMed Web of Science ®Google Scholar
• Soliman R, Youness R, Handoussa H, et al. Interplay between miR-17-5p and MALAT-1 shapes the cytokine storm in triple negative breast cancer (TNBC) tumor microenvironment. Ann Oncol. 2019;30(v769). doi: 10.1093/annonc/mdz268.024.
   Google Scholar
• Samir A, Tawab RA, El Tayebi HM. Long non‑coding RNAs XIST and MALAT1 hijack the PD‑L1 regulatory signaling pathway in breast cancer subtypes. Oncol Lett. 2021;22(2):1–12. doi: 10.3892/ol.2021.12854
   Web of Science ®Google Scholar
• Ramzy A, Youness R, Manie T, et al. 40P MALAT-1/miR-30a-5p competing endogenous (ceRNA) network releases the brakes of immune surveillance in breast cancer through its quadruple targets: PD-L1, MIF, IL-10 and TNF-α. Ann Oncol. 2021;32:S1357–S1358. doi: 10.1016/j.annonc.2021.08.2036
   Web of Science ®Google Scholar
• Chong Q-Y, You M-L, Pandey V, et al. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma. Oncotarget. 2017;8(43):74188. doi: 10.18632/oncotarget.18431
   PubMedGoogle Scholar
• Wu Y, Sarkissyan M, Ogah O, et al. Expression of MALAT1 promotes trastuzumab resistance in HER2 overexpressing breast cancers. Cancers. 2020;12(7):1918. doi: 10.3390/cancers12071918
   PubMed Web of Science ®Google Scholar
• Shaath H, Vishnubalaji R, Elango R, et al. Single-cell long noncoding RNA (lncRNA) transcriptome implicates MALAT1 in triple-negative breast cancer (TNBC) resistance to neoadjuvant chemotherapy. Cell Death Discovery, 7(1), p. 23 (2021).
   Google Scholar
• Gutschner T, Hämmerle M, Diederichs S. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med. 2013;91(7):791–801. doi: 10.1007/s00109-013-1028-y
   PubMed Web of Science ®Google Scholar
• Shen L, Chen L, Wang Y, et al. Long noncoding RNA MALAT1 promotes brain metastasis by inducing epithelial-mesenchymal transition in lung cancer. J Neurooncol. 2015;121(1):101–108. doi: 10.1007/s11060-014-1613-0
   PubMed Web of Science ®Google Scholar
• Jin D, Guo J, Wu Y, et al. M 6 a mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12(1):1–22. doi: 10.1186/s13045-019-0830-6
   PubMed Web of Science ®Google Scholar
• Yang T, Li H, Chen T, et al. LncRNA MALAT1 depressed chemo-sensitivity of NSCLC cells through directly functioning on miR-197-3p/p120 catenin axis. Mol Cells. 2019;42(3):270. doi: 10.14348/molcells.2019.2364
   PubMed Web of Science ®Google Scholar
• Tang Y, Xiao G, Chen Y, et al. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Anticancer Drugs. 2018;29(8):725–735. doi: 10.1097/CAD.0000000000000650
   PubMed Web of Science ®Google Scholar
• Li S, Mei Z, Hu HB, et al. The lncRNA MALAT1 contributes to non‐small cell lung cancer development via modulating miR‐124/STAT3 axis. J Cell Physiol. 2018;233(9):6679–6688. doi: 10.1002/jcp.26325
   PubMed Web of Science ®Google Scholar
• Wei S, Wang K, Huang X, et al. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol. 2019;33:2058738419859699. doi: 10.1177/2058738419859699
   Web of Science ®Google Scholar
• Huang J, Liu K, Song D, et al. Krüppel‐like factor 4 promotes high‐mobility group box 1‐induced chemotherapy resistance in osteosarcoma cells. Cancer Sci. 2016;107(3):242–249. doi: 10.1111/cas.12864
   PubMed Web of Science ®Google Scholar
• Jia Y, Zhang W, Liu H, et al. Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol. 2012;69(2):377–385. doi: 10.1007/s00280-011-1708-7
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang S, Zhao M, et al. LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis. Cancer Med. 2020;9(23):9138–9149. doi: 10.1002/cam4.3570
   PubMed Web of Science ®Google Scholar
• Hu Y, Lin J, Fang H, et al. Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 2018;32(10):2250–2262. doi: 10.1038/s41375-018-0104-2
   PubMed Web of Science ®Google Scholar
• Anantha RW, Simhadri S, Foo TK, et al. Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. Elife. 2017;6:e21350. doi: 10.7554/eLife.21350
   PubMed Web of Science ®Google Scholar
• Yu W, Ding J, He M, et al. Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer. Oncogene. 2019;38(8):1225–1238. doi: 10.1038/s41388-018-0463-1
   PubMed Web of Science ®Google Scholar
• Song J, Su Z, Shen Q. Long non-coding RNA MALAT1 regulates proliferation, apoptosis, migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2020;24(4):1853–1862. doi: 10.26355/eurrev_202002_20363
   PubMed Web of Science ®Google Scholar
• Wang S, Wang T, Liu D, et al. LncRNA MALAT1 aggravates the progression of non-small cell lung cancer by stimulating the expression of COMMD8 via targeting miR-613. Cancer Manage Res. 2020;12:10735. doi: 10.2147/CMAR.S263538
   PubMed Web of Science ®Google Scholar
• Zhang X, He X, Liu Y, et al. MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1. Biomed Pharmacother. 2017;93:1065–1073. doi: 10.1016/j.biopha.2017.07.005
   PubMed Web of Science ®Google Scholar
• Hu L, Wu Y, Tan D, et al. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2015;34(1):1–13. doi: 10.1186/s13046-015-0123-z
   PubMedGoogle Scholar
• Qu Y, Shao N, Yang W, et al. Association of polymorphisms in MALAT1 with the risk of esophageal squamous cell carcinoma in a Chinese population. Onco Targets Ther. 2019;12:2495. doi: 10.2147/OTT.S191155
   PubMed Web of Science ®Google Scholar
• Wang X, Li M, Wang Z, et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. J Biol Chem. 2015;290(7):3925–3935. doi: 10.1074/jbc.M114.596866
   PubMed Web of Science ®Google Scholar
• Yun Y, Zhang Y, Xu Q, et al. SOX17-mediated MALAT1-miR-199a-HIF1α axis confers sensitivity in esophageal squamous cell carcinoma cells to radiotherapy. Cell Death Discovery. 2022;8(1):270. doi: 10.1038/s41420-022-01012-6
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Hur K, et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014;35(12):2731–2739. doi: 10.1093/carcin/bgu200
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang X, Zhang T, et al. LncRNA MALAT1 promotes gastric cancer progression via inhibiting autophagic flux and inducing fibroblast activation. Cell Death Dis. 2021;12(4):368. doi: 10.1038/s41419-021-03645-4
   PubMed Web of Science ®Google Scholar
• Dai Q, Zhang T, Li C. LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathway. Cancer Manage Res. 2020;12:1929. doi: 10.2147/CMAR.S243796
   PubMed Web of Science ®Google Scholar
• Zhu K, Ren Q, Zhao Y. lncRNA MALAT1 overexpression promotes proliferation, migration and invasion of gastric cancer by activating the PI3K/AKT pathway. Oncol Lett. 2019;17(6):5335–5342. doi: 10.3892/ol.2019.10253
   PubMed Web of Science ®Google Scholar
• Xi Z, Si J, Nan J. LncRNA MALAT1 potentiates autophagy‑associated cisplatin resistance by regulating the microRNA‑30b/autophagy‑related gene 5 axis in gastric cancer. Int J Oncol. 2019;54(1):239–248. doi: 10.3892/ijo.2018.4609
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li M, Zhang Z. lncRNA MALAT1 modulates oxaliplatin resistance of gastric cancer via sponging miR-22-3p. Onco Targets Ther. 2020;13:1343. doi: 10.2147/OTT.S196619
   PubMed Web of Science ®Google Scholar
• Zheng HT, Shi DB, Wang YW, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol. 2014;7(6):3174–3181.
   PubMed Web of Science ®Google Scholar
• Wu S, Sun H, Wang Y, et al. MALAT1 rs664589 polymorphism inhibits binding to miR-194-5p, Contributing to colorectal cancer risk, growth, and metastasis. Cancer Res. 2019;79(20):5432–5441. doi: 10.1158/0008-5472.CAN-19-0773
   PubMed Web of Science ®Google Scholar
• Xie JJ, Li WH, Li X, et al. LncRNA MALAT1 promotes colorectal cancer development by sponging miR-363-3p to regulate EZH2 expression. J Biol Regul Homeost Agents. 2019;33(2):331–343.
   PubMed Web of Science ®Google Scholar
• Xu J, Xiao Y, Liu B, et al. Exosomal MALAT1 sponges miR-26a/26b to promote the invasion and metastasis of colorectal cancer via FUT4 enhanced fucosylation and PI3K/Akt pathway. J Exp Clin Cancer Res. 2020;39(1):54. doi: 10.1186/s13046-020-01562-6
   PubMed Web of Science ®Google Scholar
• Lai M-C, Yang Z, Zhou L, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29:1810–1816. doi: 10.1007/s12032-011-0004-z
   PubMed Web of Science ®Google Scholar
• Zhou D, Wang Y, Hu H, et al. lncRNA MALAT1 promotes HCC metastasis through the peripheral vascular infiltration via miRNA-613: a primary study using contrast ultrasound. World J Surg Oncol. 2022;20(1):203. doi: 10.1186/s12957-022-02655-6
   PubMed Web of Science ®Google Scholar
• Jiao F, Hu H, Yuan C, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014;32(6):2485–2492. doi: 10.3892/or.2014.3518
   PubMed Web of Science ®Google Scholar
• Li L, Chen H, Gao Y, et al. Long noncoding RNA MALAT1 promotes aggressive pancreatic cancer proliferation and metastasis via the stimulation of autophagy. Mol Cancer Ther. 2016;15(9):2232–2243. doi: 10.1158/1535-7163.MCT-16-0008
   PubMed Web of Science ®Google Scholar